222 related articles for article (PubMed ID: 35217064)
1. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
[TBL] [Abstract][Full Text] [Related]
2. Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target.
Gao Q; Yu GY; Shi JY; Li LH; Zhang WJ; Wang ZC; Yang LX; Duan M; Zhao H; Wang XY; Zhou J; Qiu SJ; Jeong LS; Jia LJ; Fan J
Oncotarget; 2014 Sep; 5(17):7820-32. PubMed ID: 25229838
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
4. Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment.
Zhou Y; Xu L; Wang Z; Liu H; Zhang X; Shu C; Zhang M; Wang T; Xu X; Pu X; He J; Wang P; Qiu Y; Xu G; Zou X; Zhu Y; Wang L
Theranostics; 2022; 12(8):3911-3927. PubMed ID: 35664077
[No Abstract] [Full Text] [Related]
5. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
[TBL] [Abstract][Full Text] [Related]
6. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.
Merino-Azpitarte M; Lozano E; Perugorria MJ; Esparza-Baquer A; Erice O; Santos-Laso Á; O'Rourke CJ; Andersen JB; Jiménez-Agüero R; Lacasta A; D'Amato M; Briz Ó; Jalan-Sakrikar N; Huebert RC; Thelen KM; Gradilone SA; Aransay AM; Lavín JL; Fernández-Barrena MG; Matheu A; Marzioni M; Gores GJ; Bujanda L; Marin JJG; Banales JM
J Hepatol; 2017 Jul; 67(1):72-83. PubMed ID: 28237397
[TBL] [Abstract][Full Text] [Related]
7. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
8. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
[TBL] [Abstract][Full Text] [Related]
9. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S
Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128
[TBL] [Abstract][Full Text] [Related]
11. Neddylation mediates ventricular chamber maturation through repression of Hippo signaling.
Zou J; Ma W; Li J; Littlejohn R; Zhou H; Kim IM; Fulton DJR; Chen W; Weintraub NL; Zhou J; Su H
Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E4101-E4110. PubMed ID: 29632206
[TBL] [Abstract][Full Text] [Related]
12. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
[TBL] [Abstract][Full Text] [Related]
13. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
14. Neddylation, a novel paradigm in liver cancer.
Delgado TC; Barbier-Torres L; Zubiete-Franco I; Lopitz-Otsoa F; Varela-Rey M; Fernández-Ramos D; Martínez-Chantar ML
Transl Gastroenterol Hepatol; 2018; 3():37. PubMed ID: 30050997
[TBL] [Abstract][Full Text] [Related]
15. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
16. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
Vallejo A; Erice O; Entrialgo-Cadierno R; Feliu I; Guruceaga E; Perugorria MJ; Olaizola P; Muggli A; Macaya I; O'Dell M; Ruiz-Fernandez de Cordoba B; Ortiz-Espinosa S; Hezel AF; Arozarena I; Lecanda F; Avila MA; Fernandez-Barrena MG; Evert M; Ponz-Sarvise M; Calvisi DF; Banales JM; Vicent S
J Hepatol; 2021 Aug; 75(2):363-376. PubMed ID: 33887357
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
Duwe L; Munoz-Garrido P; Lewinska M; Lafuente-Barquero J; Satriano L; Høgdall D; Taranta A; Nielsen BS; Ghazal A; Matter MS; Banales JM; Aldana BI; Gao YT; Marquardt JU; Roberts LR; Oliveira RC; Koshiol J; O'Rourke CJ; Andersen JB
J Hepatol; 2023 Feb; 78(2):364-375. PubMed ID: 36848245
[TBL] [Abstract][Full Text] [Related]
18. The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression.
Liu N; Zhang J; Chen W; Ma W; Wu T
J Exp Clin Cancer Res; 2023 Oct; 42(1):263. PubMed ID: 37817227
[TBL] [Abstract][Full Text] [Related]
19. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway.
Wang J; Xie C; Pan S; Liang Y; Han J; Lan Y; Sun J; Li K; Sun B; Yang G; Shi H; Li Y; Song R; Liu X; Zhu M; Yin D; Wang H; Song X; Lu Z; Jiang H; Zheng T; Liu L
Hepatology; 2016 Nov; 64(5):1606-1622. PubMed ID: 27533020
[TBL] [Abstract][Full Text] [Related]
20. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
